Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma.

被引：0
|
作者：
Patel, Krina K. [1 ]
Orlowski, Robert Z. [1 ]
Weber, Donna M. [1 ]
Wang, Michael [1 ]
Thomas, Sheeba K. [1 ]
Shah, Jatin J. [1 ]
Turturro, Francesco [1 ]
Alexanian, Raymond [1 ]
Delasalle, Kay [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8093
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes
    Wimazal, F
    Sperr, WR
    Kundi, M
    Meidlinger, P
    Fonatsch, C
    Jordan, JH
    Thalhammer-Scherrer, R
    Schwarzinger, I
    Geissler, K
    Lechner, K
    Valent, P
    LEUKEMIA RESEARCH, 2001, 25 (04) : 287 - 294
  • [42] SERUM LACTATE DEHYDROGENASE AS A PROGNOSTIC MARKER IN BREAST CANCER
    Tanna, Hardik
    Bakane, B. C.
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2015, 4 (91): : 15612 - 15614
  • [43] The lung resistance protein is an independent prognostic factor in multiple myeloma.
    Pirker, R
    Filipits, M
    Königsberg, R
    Ackermann, J
    Kittler, H
    Pohl, G
    Gisslinger, H
    Huber, H
    Ludwig, H
    Drach, J
    BLOOD, 1999, 94 (10) : 540A - 540A
  • [44] Prognostic influence of the type of graft in allogeneic transplantation for multiple myeloma.
    Gahrton, G
    Svensson, H
    Cavo, M
    Apperley, J
    Bacigalupo, A
    Björkstrand, B
    Bladé, J
    de Laurenzi, A
    de Vries, T
    Ljungman, P
    Michallet, M
    Reiffers, J
    Russell, NH
    Samson, D
    Schaefer, UW
    Schattenberg, A
    Thierry, F
    Verdonck, LF
    Vernant, JP
    Volin, L
    BONE MARROW TRANSPLANTATION, 1999, 23 : S134 - S134
  • [45] CD200 is a new prognostic factor in multiple myeloma.
    Moreaux, Jerome
    Hose, Dirk
    Reme, Thierry X.
    Jourdan, Eric
    Hundemer, Michael
    Eric, Legouffe
    Moine, Philippe
    Bourin, Philippe
    Moos, Marion
    Corre, Jill
    Mölher, Thomas
    DeVos, John
    Rossi, Jean-Francois
    Goldschmidt, Hartmut
    Klein, Bernard
    BLOOD, 2006, 108 (11) : 338B - 338B
  • [46] Soluble syndecan-1 is a prognostic marker in multiple myeloma.
    Jánosi, J
    Sebestyén, A
    Mikala, G
    Petö, M
    Jákó, J
    Domján, G
    Németh, R
    Kiss, Z
    Kopper, L
    Vályi-Nagy, I
    BLOOD, 2003, 102 (11) : 362B - 362B
  • [47] Advanced age is not an adverse prognostic factor for patients with multiple myeloma.
    Dimopoulos, M
    Pouli, A
    Zervas, K
    Gika, D
    Repousis, P
    Mitsouli, C
    Grigoraki, V
    Anagnostopoulos, N
    Stamatellou, M
    Symeonidis, A
    Maniatis, A
    BLOOD, 2002, 100 (11) : 600A - 600A
  • [48] Evaluation of serum Cystatin-C as a prognostic and predictive factor in patients with newly diagnosed multiple myeloma.
    Reddy, Rakesh
    Gupta, Ritu
    Mathur, Nitin
    Rani, Lata
    Sharma, Atul
    Kumar, Lalit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Serum syndecan (CD138) levels are increased in patients with symptomatic multiple myeloma compared to normal controls, MGUS, and smoldering myeloma.
    Kumar, S
    Ahmann, G
    Witzig, TE
    Kyle, RA
    Greipp, PR
    BLOOD, 2002, 100 (11) : 806A - 807A
  • [50] Prognostic value of cytogenetics in multiple myeloma
    Seong, C
    Delasalle, K
    Hayes, K
    Weber, D
    Dimopoulos, M
    Swantkowski, J
    Huh, Y
    Glassman, A
    Champlin, R
    Alexanian, R
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (01) : 189 - 194
12345